Loading…
Neonc Technologies Holdings Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in NTHI.
▼ -75.2% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ENGNenGene Therapeutics Inc. | $1.83 | — | 0.5x | — | -52.59% | $122.26M |
| GNLXGENELUX Corp | $2.66 | — | 7.5x | — | -177.93% | $120.35M |
| PMNProMIS Neurosciences Inc. | $13.79 | — | 2.5x | — | -172.30% | $123.62M |
| QUCYQuantum Cyber N.V. | $1.42 |
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Company description provided by Yahoo Finance.
| — |
| 1.7x |
| — |
| -212.53% |
| $119.38M |
| JYNTJOINT Corp | $8.38 | 59.9x | 7.2x | — | 10.62% | $118.52M |
| ANIXAnixa Biosciences Inc | $3.48 | — | 8.1x | — | -71.97% | $118.4M |